| Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. B Fisk, TL Blevins, JT Wharton, CG Ioannides The Journal of experimental medicine 181 (6), 2109-2117, 1995 | 764 | 1995 |
| BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells TD Shellenberger, M Wang, M Gujrati, A Jayakumar, RM Strieter, ... Cancer research 64 (22), 8262-8270, 2004 | 302 | 2004 |
| Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. CG Ioannides, B Fisk, KR Jerome, T Irimura, JT Wharton, OJ Finn Journal of immunology (Baltimore, Md.: 1950) 151 (7), 3693-3703, 1993 | 293 | 1993 |
| Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients GE Peoples, JM Gurney, MT Hueman, MM Woll, GB Ryan, CE Storrer, ... Journal of Clinical Oncology 23 (30), 7536-7545, 2005 | 278 | 2005 |
| Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US Military Cancer Institute Clinical Trials … GE Peoples, JP Holmes, MT Hueman, EA Mittendorf, A Amin, S Khoo, ... Clinical Cancer Research 14 (3), 797-803, 2008 | 217 | 2008 |
| Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. CG Ioannides, RS Freedman, CD Platsoucas, S Rashed, YP Kim Journal of immunology (Baltimore, Md.: 1950) 146 (5), 1700-1707, 1991 | 185 | 1991 |
| T cell recognition of human tumors: implications for molecular immunotherapy of cancer CG Ioannides, TL Whiteside Clinical immunology and immunopathology 66 (2), 91-106, 1993 | 182 | 1993 |
| Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369–377) combined with granulocyte macrophage colony-stimulating factor in HLA … JL Murray, ME Gillogly, D Przepiorka, H Brewer, NK Ibrahim, DJ Booser, ... Clinical Cancer Research 8 (11), 3407-3418, 2002 | 167 | 2002 |
| Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene CG Ioannides, B Fisk, D Fan, WE Biddison, JT Wharton, CA O'brian Cellular Immunology 151 (1), 225-234, 1993 | 167 | 1993 |
| Oxidant-induced S-glutathiolation inactivates protein kinase C-α (PKC-α): a potential mechanism of PKC isozyme regulation NE Ward, JR Stewart, CG Ioannides, CA O'Brian Biochemistry 39 (33), 10319-10329, 2000 | 161 | 2000 |
| Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism JR Stewart, NE Ward, CG Ioannides, CA O'Brian Biochemistry 38 (40), 13244-13251, 1999 | 142 | 1999 |
| Synthetic microRNA designed to target glioma-associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells N Tsuda, S Ishiyama, Y Li, CG Ioannides, JL Abbruzzese, DZ Chang Clinical Cancer Research 12 (21), 6557-6564, 2006 | 121 | 2006 |
| Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites CG Ioannides, CD Platsoucas, S Rashed, JT Wharton, CL Edwards, ... Cancer Research 51 (16), 4257-4265, 1991 | 119 | 1991 |
| Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers GE Peoples, BW Anderson, TV Lee, JL Murray, AP Kudelka, JT Wharton, ... Clinical cancer research 5 (12), 4214-4223, 1999 | 89 | 1999 |
| Breast cancer cells expressing stem cell markers CD44+ CD24lo are eliminated by Numb-1 peptide-activated T cells T Mine, S Matsueda, Y Li, H Tokumitsu, H Gao, C Danes, KK Wong, ... Cancer immunology, immunotherapy 58, 1185-1194, 2009 | 80 | 2009 |
| Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. TM Tuttle, BW Anderson, WE Thompson, JE Lee, A Sahin, TL Smith, ... Clinical cancer research: an official journal of the American Association …, 1998 | 79 | 1998 |
| Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53) N Yen, CG Ioannides, K Xu, SG Swisher, DD Lawrence, BL Kemp, ... Cancer gene therapy 7 (4), 530-536, 2000 | 75 | 2000 |
| Synthetic microRNA and double-stranded RNA targeting the 3'-untranslated region of HER-2/neu mRNA inhibit HER-2 protein expression in ovarian cancer cells N Tsuda, K Kawano, CL Efferson, CG Ioannides International journal of oncology 27 (5), 1299-1306, 2005 | 70 | 2005 |
| Clinical studies of vaccines targeting breast cancer BK Ko, K Kawano, JL Murray, ML Disis, CL Efferson, HM Kuerer, ... Clinical cancer research 9 (9), 3222-3234, 2003 | 69 | 2003 |
| Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model R Miyahara, S Banerjee, K Kawano, C Efferson, N Tsuda, Y Miyahara, ... Cancer gene therapy 13 (8), 753-761, 2006 | 66 | 2006 |
